A broad range of anti-tumor activity of pralsetinib on multiple advanced RET fusion-positive solid tumors in addition to NSCLC has also been reported; tumor type includes papillary thyroid cancers, undifferentiated thyroid cancer, pancreatic cancer, colon cancer, etc.[128]. Here, RET is linked to non-small cell lung carcinoma.